Open Access
- 5 June 2025
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60223
Abstract
Introduction and Purpose: Androgenetic alopecia (AGA) is the most common form of hair loss, affecting both men and women. It involves progressive miniaturization of hair follicles due to dihydrotestosterone (DHT) and genetic factors. AGA has cosmetic and psychological impacts and is linked to systemic conditions such as cardiovascular and metabolic disorders. Although treatments like finasteride and minoxidil are FDA-approved, alternative therapies are being explored to improve outcomes and reduce side effects. This review provides an updated overview of AGA pathogenesis and emerging treatment options. Material and Methods: A comprehensive literature review was conducted, analyzing recent studies on AGA pathophysiology, genetics, and treatments. Findings on FDA-approved drugs, alternative pharmacologic therapies, mesotherapy, and low-level light therapy (LLLT) were evaluated for efficacy and safety. State of Knowledge: AGA pathogenesis includes hormonal, genetic, and environmental components. DHT binds to androgen receptors in vulnerable hair follicles, leading to miniaturization. Genetic susceptibility involves loci like AR/EDA2R. While finasteride and minoxidil remain mainstays, newer treatments—such as dutasteride, androgen receptor antagonists (e.g., spironolactone, clascoterone, pyrilutamide), mesotherapy, and low-dose oral minoxidil—show promise. LLLT, particularly red LED light (630–660 nm), stimulates hair growth and reduces inflammation. Clinical studies suggest combination therapies are more effective than monotherapy. Conclusions: AGA is complex and requires long-term management. Finasteride and minoxidil are effective, but alternative treatments like dutasteride, mesotherapy, androgen blockers, and red LED therapy offer promising results. Combination therapy appears most effective, though more research is needed to standardize protocols and confirm long-term safety.Keywords
This publication has 21 references indexed in Scilit:
- Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopeciaExpert Opinion on Emerging Drugs, 2024
- Updated Review of Treatment of Androgenetic AlopeciaFacial Plastic Surgery Clinics of North America, 2024
- Androgenetic Alopecia: Therapy UpdateDrugs, 2023
- Early onset female pattern hair loss: A case–control study for analyzing clinical features and genetic variantsJournal of Dermatological Science, 2022
- A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical studyDermatologic Therapy, 2020
- Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literatureJournal of Dermatological Treatment, 2020
- Clascoterone as a novel treatment for androgenetic alopeciaClinical and Experimental Dermatology, 2020
- The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysisAesthetic Plastic Surgery, 2020
- Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patientsDermatologic Therapy, 2015
- A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair lossJournal of the American Academy of Dermatology, 2004